Howard Horn - Mar 6, 2025 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
Chief Financial Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Mar 6, 2025
Transactions value $
-$72,114
Form type
4
Date filed
3/10/2025, 12:53 PM
Previous filing
Mar 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Sale -$72.1K -1.79K -1.65% $40.40 106K Mar 6, 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.73 to $41.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.